Preferred Label : Tepotinib Hydrochloride;
NCIt synonyms : Tepotinib Hydrochloride Monohydrate;
NCIt definition : The hydrochloride salt form of tepotinib, an orally bioavailable inhibitor of MET
tyrosine kinase with potential antineoplastic activity. Upon oral administration,
tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction
pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The
receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR),
is the product of the proto-oncogene c-Met and is overexpressed or mutated in many
tumor cell types; this protein plays key roles in tumor cell proliferation, survival,
invasion, and metastasis, and tumor angiogenesis.;
UNII : VY5YX2TQ1F;
InChIKey : KZVOMLRKFJUTLK-UHFFFAOYSA-N;
CAS number : 1946826-82-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1946826-82-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Tepmetko;
NCI Metathesaurus CUI : CL1405742;
Origin ID : C171761;
UMLS CUI : C5419289;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/tepmetko-cancer-du-poumon-non-a-petites-cellules-6026.html
2022
false
false
false
Canada
French
insurance, health, reimbursement
drug evaluation
canada
tepmetko
Tepotinib Hydrochloride
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
MET Exon 14 Skipping Mutation
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tepotinib
tepotinib
tepotinib
antineoplastic agents
antineoplastic agents
bronchial neoplasms
carcinoma, non-small-cell lung
drug approval
europe
pregnancy
breast feeding
drug interactions
Product containing precisely tepotinib (as tepotinib hydrochloride) 225 milligram/1
each conventional release oral tablet (clinical drug)
tepmetko
Tepotinib Hydrochloride
adult
bronchial neoplasms
carcinoma, non-small-cell lung
mutation
MET Exon 14 Skipping Mutation
proto-oncogene proteins c-met
protein kinase inhibitors
protein kinase inhibitors
administration, oral
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
---
